PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Prices as of the 2026-10-02 close
Prestige Biopharma continues to advance its pipeline with the European commercialization of the Herceptin biosimilar Tuznue and positive Phase 3 topline data for the Avastin biosimilar HD204, while persistent operating losses and difficulties in convertible bond financing weigh on its balance sheet.
The Herceptin biosimilar Tuznue (HD201), approved in Europe in 2024, expanded its distribution network through a 2025 agreement with Teva.
The Avastin biosimilar HD204 achieved Phase 3 topline data meeting equivalence margins versus the originator, with regulatory filings planned sequentially in the UK, Europe, and the US in the second half of 2026.
Annual revenue remains small relative to operating costs, with operating losses persisting throughout 2022-2025.
A planned convertible bond issuance of up to KRW 100 billion, launched in early 2026, was scaled back and delayed amid difficulties attracting investors.
Follow-on pipeline assets including the pancreatic cancer antibody PBP1510 and the Humira biosimilar PBP1502 point to a series of upcoming clinical and regulatory milestones.
Prestige Biopharma is a holding-style biopharmaceutical company developing antibody drugs and biosimilars, operating an integrated research-development-manufacturing value chain through its KOSDAQ-listed CDMO subsidiary Prestige Biologics and an R&D subsidiary. Its stake in Prestige Biologics is reported at 40.03%.
The core biosimilar product is Tuznue (HD201), a Herceptin (trastuzumab) biosimilar that received EU marketing authorization in 2024 and expanded its distribution network through a 2025 agreement with global pharmaceutical company Teva.
The follow-on Avastin (bevacizumab) biosimilar HD204 is covered by supply agreements with multinational partners Intas and Accord Healthcare across Europe, the US, the UK, Canada, Brazil, Mexico, the Middle East and North Africa, and Southeast Asia.
In the new-drug segment, the pancreatic cancer-targeting antibody PBP1510 has secured orphan drug designation and fast-track status from US, European, and Korean regulators and is in Phase 1/2a trials, while the Humira biosimilar PBP1502 is in Phase 1.
In the Herceptin biosimilar market, established competitors include Celltrion's Herzuma, Samsung Bioepis's Ontruzant, Amgen/Allergan's Kanjinti, and Pfizer's Trazimera, making price competitiveness and local partnerships key differentiators for a late entrant.
The company recently reorganized its R&D structure into three pillars—Global Quality Management, Global CMC & Analytical Science, and Integrated Pipeline Management—shifting emphasis from clinical operations toward regulatory approval and commercialization. Its CDMO subsidiary Prestige Biologics appears to be expanding its revenue base through new contract wins.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2024Q4 | — | -₩9.4B | — |
| 2025Q1 | ₩2.3B | -₩23.7B | −1051.6% |
| 2025Q2 | ₩7.4B | -₩17.8B | −242.4% |
| 2025Q3 | — | -₩9.7B | — |
| 2025Q4 | ₩5.3B | -₩13.8B | −258.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩0 | -₩66B | -₩238.3B | — | −52.9% | 16.3% |
| 2023 | ₩200M | -₩71.2B | ₩18B | −42988.4% | 3.9% | 35.8% |
| 2024 | ₩700M | -₩63.8B | -₩33.4B | −9111.2% | −7.8% | 38.1% |
| 2025 | ₩13.8B | -₩65B | ₩21.5B | −470.1% | 5.2% | 46.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-23
Consolidated revenue rose from zero in 2022 to KRW 0.17 billion in 2023, KRW 0.7 billion in 2024, and KRW 13.8 billion in 2025, though the absolute scale remains small.
Over the same period, operating losses stayed in the range of KRW 63.8-71.2 billion each year (KRW 66.0 billion in 2022, KRW 71.2 billion in 2023, KRW 63.8 billion in 2024, KRW 65.0 billion in 2025), producing extreme operating margins of -42,988.4% in 2023, -9,111.2% in 2024, and -470.1% in 2025 due to the small revenue base.
Net income attributable to owners swung from a large loss of KRW 238.3 billion in 2022 to a profit of KRW 18.0 billion in 2023, a loss of KRW 33.4 billion in 2024, and a profit of KRW 21.5 billion in 2025, with profitable years occurring even as operating losses persisted, suggesting a significant role for non-operating items.
On a quarterly basis, losses continued through the first half of 2025, with an operating loss of KRW 23.7 billion and owners' net loss of KRW 12.1 billion in the first quarter, followed by an operating loss of KRW 17.8 billion and owners' net loss of KRW 14.4 billion in the second quarter.
In the third quarter, the operating loss narrowed to KRW 9.7 billion, yet owners' net income swung to a large profit of KRW 56.5 billion—given the continuing operating loss in the same quarter, this points to the influence of a substantial one-off item below the operating line.
The fourth quarter reverted to a loss, with revenue of KRW 5.3 billion, an operating loss of KRW 13.8 billion, and an owners' net loss of KRW 8.5 billion.
Operating cash flow remained consistently negative, from -KRW 51.7 billion in 2022 to -KRW 50.3 billion in 2025, reflecting ongoing cash consumption tied to R&D and commercialization investment.
The debt ratio has steadily risen from 16.3% in 2022 to 35.8% in 2023, 38.1% in 2024, and 46.7% in 2025, indicating gradually increasing financial leverage.
The Herceptin biosimilar market is a mature market already populated by multiple competing products; representative approved trastuzumab intravenous biosimilars in the US and EU include Amgen/Allergan's Kanjinti, Pfizer's Trazimera, Samsung Bioepis's Ontruzant, and Celltrion's Herzuma.
In terms of market size, the global Herceptin biosimilar market was valued at $1.795 billion in 2021 and is projected to grow at 23.2% annually to reach $11.287 billion by 2030, a growing market into which Prestige Biopharma has entered as a late mover.
The Avastin (bevacizumab) market is also expanding, with the global bevacizumab market estimated at roughly $5.651 billion in 2023 and forecast to grow at a 9.8% compound annual rate to surpass $8.56 billion by 2030, and biosimilar penetration in advanced markets such as Europe already exceeding 60-70%, rapidly displacing originator products.
The regulatory environment also shows signs of turning more favorable, as the US FDA has recently been pursuing policy changes to simplify biosimilar approval procedures and reduce the burden of comparative clinical trials, potentially benefiting later entrants.
On competitive positioning, Prestige Biopharma's European approval of Tuznue came as the third such approval among Korean companies, following Celltrion and Samsung Bioepis, indicating it entered the market later than Korea's leading biosimilar makers.
In the CDMO segment, subsidiary Prestige Biologics has stated it signed a total of six new CDMO contracts worth approximately KRW 41.2 billion with domestic and overseas clients during fiscal year 2026, benefiting from expanding contract manufacturing demand.
However, it was also noted that losses widened despite the revenue increase, with impairment charges on inventory, convertible bonds, and some production facilities cited as the main drivers.
The company has stated that since launching its first commercial pipeline asset Tuznue in major European countries last year, it has designated this year as a period of revenue expansion and next year as a point for securing stable market share, planning to accelerate market penetration through country-specific entry, price competitiveness, and local partnerships.
For its second commercialization asset, HD204, the company plans to file for marketing authorization in the US, UK, and other markets in the second half of this year, with topline data already in hand making the progress of this timeline the key variable to watch.
The drug candidate PBP1510 is currently in global Phase 1/2a trials, and the company has used this pipeline to pursue business development, having participated in the BIO International Convention 2026 held in San Diego in June 2026 to discuss partnerships with global pharmaceutical and biotech companies.
For the Humira biosimilar PBP1502, the company set a target of filing for marketing authorization in the second half of 2026 and then rapidly penetrating markets exempt from Phase 3 trials, such as the UK, Canada, and developing countries, to generate revenue.
However, a notable gap exists between the company's previously stated medium-to-long-term roadmap—KRW 300 billion in annual revenue by 2026 and a KRW 30 trillion market capitalization with KRW 2.5 trillion in annual revenue by 2030—and actual 2025 revenue of roughly KRW 13.8 billion, meaning achievement of these targets hinges on the pace of future pipeline commercialization.
On the financing side, it is a positive that on September 21, 2026, Samduk Accounting Corporation issued an 'unqualified' audit opinion on both consolidated and standalone financial statements and stated that going-concern uncertainty did not apply, though whether additional convertible bond financing is successfully completed remains a variable to monitor.
The company has sustained large annual operating losses while still maintaining positive net assets, so its shares tend to trade at levels close to or somewhat below book value per share.
With no dividend payment history and a policy of no dividends, valuation hinges less on income return expectations and more on the progress of pipeline commercialization.
Given that owners' net income turned profitable in 2023 and 2025 even as operating losses persisted, earnings metrics alone should be interpreted cautiously rather than as evidence of a structural profitability turnaround.
The rapid recent growth in revenue is a positive development, but the absolute scale remains small, warranting caution when interpreting market-capitalization-relative revenue and earnings metrics.
Going forward, the approval timelines for HD204 and PBP1502, along with the completion of additional financing, are likely to continue influencing how the balance sheet is assessed.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-23
Tuznue expanded its distribution network through a 2025 agreement with Teva after receiving EU marketing authorization in 2024. As the company's first commercialized pipeline asset since its founding, it could serve as a foundation for broadening the revenue base going forward.
A strategy emphasizing country-specific entry and price competitiveness will be a key variable determining the pace of market penetration.
HD204 secured Phase 3 topline data meeting equivalence margins versus the originator in its global trial. Broad regional supply agreements with Intas and Accord Healthcare are already in place, creating a structure for rapid revenue recognition once approved.
The planned sequential filing in the UK, Europe, and the US in the second half of 2026 is the next milestone to watch.
The pancreatic cancer antibody PBP1510, which has secured orphan drug and fast-track designations in the US, Europe, and Korea, is progressing through global Phase 1/2a trials. The Humira biosimilar PBP1502, in Phase 1, is another candidate revenue source. The FDA's biosimilar approval simplification policy could also work in favor of later entrants.
Operating losses of KRW 60-70 billion persisted every year from 2022 through 2025, with operating margins remaining extremely negative relative to revenue. While revenue growth is a positive sign, it has not yet kept pace with the scale of losses.
Even in years when owners' net income turned profitable, this appears attributable to non-operating factors, meaning a structural recovery in core business profitability has not yet been confirmed.
A planned convertible bond issuance of up to KRW 100 billion, launched in early 2026, faced difficulty attracting investors, leading to a reduced size and delayed board timeline.
Group-wide liquidity pressure is also evident, as affiliate Prestige Biologics has pursued additional borrowing and extended convertible bond maturities. The debt ratio has risen steadily from 16.3% in 2022 to 46.7% in 2025, reflecting continued expansion of financial leverage.
In the third quarter of 2025, owners' net income posted a large profit of KRW 56.5 billion, yet the operating loss continued in the same quarter. This appears attributable to a substantial one-off item below the operating line, making it difficult to view as evidence of repeatable earnings power. The fourth quarter reverted to a loss, underscoring significant quarter-to-quarter volatility.
If the convertible bond issuance is not completed as planned, funding needed for R&D and commercialization investment could be delayed. The group's financing structure continues to rely on borrowing and convertible bond maturity extensions, raising the possibility of increased future interest expense. It is worth noting, however, that a recent audit report stated that going-concern uncertainty did not apply.
There is a possibility that the filing and approval timelines for HD204 and PBP1502 may not proceed as planned. Given that Tuznue's European approval process previously experienced longer-than-expected review by the EMA, similar delays could recur for follow-on pipeline assets.
Changes in regulatory requirements or requests for additional data could affect the timing of commercialization.
The Herceptin and Avastin biosimilar markets are already occupied by well-capitalized incumbents with established distribution networks, including Celltrion, Samsung Bioepis, Amgen, and Pfizer.
As a late entrant, Prestige Biopharma must rely on price competitiveness and partnerships, and securing market share could become more difficult if competitors respond with pricing actions or if new entrants emerge.
Competition for share may be especially intense in the European market, where biosimilar penetration is already high.
Watch for progress on HD204's marketing authorization filings in the UK, Europe, and the US. If the plan proceeds on schedule, it could serve as the next catalyst for revenue expansion as the company's second commercial asset.
Check whether the Humira biosimilar PBP1502 files for marketing authorization. A key point to watch is whether the strategy of entering Phase 3-exempt countries is executed.
Monitor whether the pancreatic cancer antibody PBP1510 advances into Phase 2a trials. Advancement would strengthen the rationale for valuing the new-drug pipeline.
Confirm whether the scaled-back and delayed convertible bond issuance is ultimately completed and on what final terms. This is a variable with direct implications for financial leverage and available liquidity.
Check the timing of the next regular quarterly report to assess whether the revenue growth trend and changes in loss size continue.
Prestige Biopharma stands at a transition point from years of development toward commercialization, marked by Tuznue's European rollout and the securing of Phase 3 topline data for HD204.
However, operating losses exceeding KRW 60 billion have persisted every year from 2022 through 2025, and revenue remains insufficient to offset these losses.
While owners' net income turned profitable in certain years, this appears attributable to non-operating one-off items, making it premature to confirm a structural recovery in core business profitability.
The scaling back and delay of the convertible bond issuance launched in early 2026, amid difficulty attracting investors, remains a financing risk going forward, and the debt ratio has been rising each year.
On the other hand, a recent audit report found that going-concern uncertainty did not apply, and filing timelines for HD204 and PBP1502 are set for the second half of 2026, meaning a number of verifiable events lie ahead over the coming months.
Investors will want to monitor both the actual execution of the pipeline's approval timeline and the completion of the company's financing plans.
Report written 2026-09-23 · Data as of 2026-09-22
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.